Browse FAAH

Summary
SymbolFAAH
Namefatty acid amide hydrolase
Aliases FAAH-1; PSAB; anandamide amidohydrolase 1; oleamide hydrolase 1; Fatty-acid amide hydrolase 1
Chromosomal Location1p35-p34
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Endomembrane system Single-pass membrane protein Cytoplasm, cytoskeleton Note=Seems to be attached to intracellular membranes and a portion of the cytoskeletal network.
Domain PF01425 Amidase
Function

Degrades bioactive fatty acid amides like oleamide, the endogenous cannabinoid, anandamide and myristic amide to their corresponding acids, thereby serving to terminate the signaling functions of these molecules. Hydrolyzes polyunsaturated substrate anandamide preferentially as compared to monounsaturated substrates.

> Gene Ontology
 
Biological Process GO:0001676 long-chain fatty acid metabolic process
GO:0006631 fatty acid metabolic process
GO:0006690 icosanoid metabolic process
GO:0009062 fatty acid catabolic process
GO:0016042 lipid catabolic process
GO:0016054 organic acid catabolic process
GO:0019369 arachidonic acid metabolic process
GO:0033559 unsaturated fatty acid metabolic process
GO:0044242 cellular lipid catabolic process
GO:0044282 small molecule catabolic process
GO:0046395 carboxylic acid catabolic process
GO:0072329 monocarboxylic acid catabolic process
Molecular Function GO:0016298 lipase activity
GO:0016810 hydrolase activity, acting on carbon-nitrogen (but not peptide) bonds
GO:0016811 hydrolase activity, acting on carbon-nitrogen (but not peptide) bonds, in linear amides
GO:0016874 ligase activity
GO:0016879 ligase activity, forming carbon-nitrogen bonds
GO:0016884 carbon-nitrogen ligase activity, with glutamine as amido-N-donor
GO:0017064 fatty acid amide hydrolase activity
GO:0047372 acylglycerol lipase activity
GO:0052689 carboxylic ester hydrolase activity
GO:0103073 anandamide amidohydrolase activity
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa04723 Retrograde endocannabinoid signaling
Reactome R-HSA-2142753: Arachidonic acid metabolism
R-HSA-1430728: Metabolism
R-HSA-556833: Metabolism of lipids and lipoproteins
Summary
SymbolFAAH
Namefatty acid amide hydrolase
Aliases FAAH-1; PSAB; anandamide amidohydrolase 1; oleamide hydrolase 1; Fatty-acid amide hydrolase 1
Chromosomal Location1p35-p34
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between FAAH and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolFAAH
Namefatty acid amide hydrolase
Aliases FAAH-1; PSAB; anandamide amidohydrolase 1; oleamide hydrolase 1; Fatty-acid amide hydrolase 1
Chromosomal Location1p35-p34
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of FAAH in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolFAAH
Namefatty acid amide hydrolase
Aliases FAAH-1; PSAB; anandamide amidohydrolase 1; oleamide hydrolase 1; Fatty-acid amide hydrolase 1
Chromosomal Location1p35-p34
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of FAAH in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.6520.105
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.250.754
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.9490.122
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.8840.0474
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.850.649
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.9260.687
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.0770.842
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.6310.369
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.8610.253
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.1430.918
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.2760.883
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0630.665
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of FAAH in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.15.91.21
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103100101
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 41407.1-7.11
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27737.41.460.177
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27597.41.75.70.231
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 111307.7-7.71
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 51208.3-8.31
Summary
SymbolFAAH
Namefatty acid amide hydrolase
Aliases FAAH-1; PSAB; anandamide amidohydrolase 1; oleamide hydrolase 1; Fatty-acid amide hydrolase 1
Chromosomal Location1p35-p34
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of FAAH. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolFAAH
Namefatty acid amide hydrolase
Aliases FAAH-1; PSAB; anandamide amidohydrolase 1; oleamide hydrolase 1; Fatty-acid amide hydrolase 1
Chromosomal Location1p35-p34
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of FAAH. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by FAAH.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolFAAH
Namefatty acid amide hydrolase
Aliases FAAH-1; PSAB; anandamide amidohydrolase 1; oleamide hydrolase 1; Fatty-acid amide hydrolase 1
Chromosomal Location1p35-p34
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of FAAH. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolFAAH
Namefatty acid amide hydrolase
Aliases FAAH-1; PSAB; anandamide amidohydrolase 1; oleamide hydrolase 1; Fatty-acid amide hydrolase 1
Chromosomal Location1p35-p34
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of FAAH expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolFAAH
Namefatty acid amide hydrolase
Aliases FAAH-1; PSAB; anandamide amidohydrolase 1; oleamide hydrolase 1; Fatty-acid amide hydrolase 1
Chromosomal Location1p35-p34
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between FAAH and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolFAAH
Namefatty acid amide hydrolase
Aliases FAAH-1; PSAB; anandamide amidohydrolase 1; oleamide hydrolase 1; Fatty-acid amide hydrolase 1
Chromosomal Location1p35-p34
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting FAAH collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting FAAH.
ID Name Drug Type Targets #Targets
DB00316AcetaminophenSmall MoleculeFAAH, GSTP1, PTGS1, PTGS2, TRPV15
DB00599ThiopentalSmall MoleculeCHRM3, CHRNA4, CHRNA7, FAAH, GABRA1, GABRA2, GABRA3, GABRA4, GABRA ......12
DB02465Methoxy arachidonyl fluorophosphonateSmall MoleculeFAAH1
DB068941-DODECANOLSmall MoleculeFAAH1
DB083854-(quinolin-3-ylmethyl)piperidine-1-carboxylic acidSmall MoleculeFAAH1
DB084004-(3-{[5-(trifluoromethyl)pyridin-2-yl]oxy}benzyl)piperidine-1-carboxylic acidSmall MoleculeFAAH1